Longitudinal analysis of genetic and environmental interplay in human metabolic profiles and the implication for metabolic health

Jing Wang[1#], Alberto Zenere[1#], Xingyue Wang[1#], Göran Bergström[2], Fredrik Edfors[3], Mathias Uhlén[3], Wen Zhong[1*]

[1] Science for Life Laboratory, Department of Biomedical and Clinical Sciences (BKV), Linköping University, Linköping, Sweden.

[2] Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, and Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

[3] Department of Protein Science, KTH - Royal Institute of Technology, Stockholm, Sweden

* To whom correspondence should be addressed: Wen Zhong

Address: Department of Biomedical and Clinical Sciences (BKV), Linköping University, SE-581 83, Linköping

Email: wen.zhong@liu.se

Phone: + 46 729419808

# Equal contribution; these authors share first authorship.

Abstract

Background

Understanding how genetics and environmental factors shape human metabolic profiles is crucial for advancing metabolic health. Variability in metabolic profiles, influenced by genetic makeup, lifestyle, and environmental exposures, plays a critical role in disease susceptibility and progression.

Methods

We conducted a two-year longitudinal study involving 101 clinically healthy individuals aged 50 to 65, integrating genomics, metabolomics, lipidomics, proteomics, clinical measurements, and lifestyle questionnaire data from repeat sampling. We evaluated the influence of both external and internal factors, including genetic predispositions, lifestyle factors, and physiological conditions, on individual metabolic profiles. Additionally, we developed an integrative metabolite-protein network to analyze protein-metabolite associations under both genetic and environmental regulations.

Results

Our findings highlighted the significant role of genetics in determining metabolic variability, identifying 22 plasma metabolites as genetically predetermined. Environmental factors such as seasonal variation, weight management, smoking, and stress also significantly influenced metabolite levels. The integrative metabolite-protein network comprised 5,649 significant protein-metabolite pairs and identified 87 causal metabolite-protein associations under genetic regulation, validated by showing a high replication rate in an independent cohort. This network revealed stable and unique protein-metabolite profiles for each individual, emphasizing metabolic individuality. Notably, our results demonstrated the importance of plasma proteins in capturing individualized metabolic variabilities. Key proteins representing individual metabolic profiles were identified and validated in the UK Biobank, showing great potential for predicting metabolic diseases and metabolic risk assessment.

Conclusions

Our study provides longitudinal insights into how genetic and environmental factors shape human metabolic profiles, revealing unique and stable individual metabolic profiles. Plasma proteins emerged

as key indicators for capturing the variability in human metabolism and assessing metabolic risks. These findings offer valuable tools for personalized medicine and the development of diagnostics for metabolic diseases.

Keywords

Human metabolism, genetics, proteomics, metabolomics, lifestyle, environment, metabolic risk

Background

The human metabolome is dynamic, and the variability in human metabolic profiles across individuals is shaped by each person's unique genetic makeup, lifestyle, and environmental exposures[1,2]. These factors play critical roles in disease susceptibility and progression, including obesity, diabetes, hypertension, cardiovascular disease and other metabolic abnormalities[3–6]. Despite significant advancements in metabolomics, the determinants of individual metabolic variability remain incompletely understood. Twin studies have revealed a broad range of heritability for metabolite levels in human plasma[7,8], and genome-wide association studies (GWAS) have identified numerous genetic variants influencing metabolite levels (mQTL, metabolite quantitative trait loci)[9–13]. This demonstrates the important role of genetics in human metabolism for the understanding of individual metabolic diversity. Beyond genetics, human metabolic profiles are also influenced by various factors such as obesity[14–16], lifestyle [17], diet[2,18,19], microbiome[2,18,19], medications[20], and other environmental exposures. For instance, by analyzing fasting plasma profiles of 1,183 metabolites in 1,679 samples from 1,368 individuals, Chen et al.[21] found that diet, genetics and the gut microbiome could explain 9.3%, 3.3% and 12.8%, respectively, of the inter-individual variations in plasma metabolomics.

However, these GWAS and association studies often overlook the temporal dynamics and environmental interactions that continuously influence the metabolome. Seasonal variations, for instance, introduce another layer of complexity in metabolite levels[22–24], reflecting changes in environmental conditions, dietary habits, physical activity, and other lifestyle factors[25,26]. The heterogeneity in metabolite levels among individuals further underscores their multifaceted roles in

various biological processes[27,28]. To accurately contextualize this variability in human metabolism, incorporating longitudinal molecular data from the same individuals is crucial. This approach allows for the monitoring of dynamics in metabolite levels in response to external influences and internal physiological changes, providing a more comprehensive understanding of individual metabolite variability[5,29,30]. In addition, longitudinal data can reveal temporal metabolic regulation patterns that are not apparent in cross-sectional studies[31], offering deeper insights into the dynamic interplay between genetic predispositions and environmental factors and advancing precision medicine for metabolic health.

Here, we conducted a detailed longitudinal multi-omics analysis involving 101 individuals aged 50-65 over two years to explore the dynamics and individual differences in metabolic profiles. The influences of genetic predispositions, lifestyle factors, and physiological conditions on individual metabolic profiles have been investigated. Additionally, we established an integrative metabolite-protein network and identified key proteins and metabolites associated with human metabolic risk. This work contributes to a more comprehensive understanding of individual metabolite variability and advances our knowledge in more personalized approaches to monitoring metabolic health.

Methods

The wellness profiling study

The Swedish SciLifeLab SCAPIS Wellness Profiling (S3WP) study is an observational study aimed at gathering longitudinal clinical and molecular data from a community-based cohort. This study derived from the Swedish CArdioPulmonary bioImage Study (SCAPIS), which is a prospective observational study with 30,154 individuals aged 50 to 65 years at enrollment, randomly selected from the general Swedish population between 2015 and 2018 [32]. In SCAPIS, no exclusion criteria are applied except the inability to understand written and spoken Swedish for informed consent. In the S3WP study, we enrolled 101 healthy individuals with the following exclusion criteria: (1) previously received health care for myocardial infarction, stroke, peripheral artery disease, or diabetes, (2) presence of any clinically significant disease which, in the opinion of the investigator, may interfere with the results or

99 the subject's ability to participate in the study, (3) any major surgical procedure or trauma within 4
100 weeks of the first study visit, or (4) medication for hypertension or hyperlipidemia. Before enrolling in
101 the S3WP study, all subjects had been extensively assessed by SCAPIS [32]. Throughout the duration of
102 the S3WP study, follow-up visits are conducted every third month (±2 weeks) in the first year and
103 approximately a 6-month interval in the second year. All subjects were fasting overnight (at least 8 h)
104 before the visits. Lifestyle questionnaires, anthropometric measurements, clinical measurements, and
105 plasma proteome profiling, metabolome profiling and lipidome profiling were examined at each of the
106 follow-up visit. Whole genome sequencing data were detected at the baseline (**Fig. 1a, Additional file**
107 **2: Table S1**). The study has been approved by the Ethical Review Board of Göteborg, Sweden
108 (registration number 407-15), and all participants provided written informed consent. The study
109 protocol adheres to the ethical guidelines outlined in the 1975 Declaration of Helsinki.

110 **Self-reported questionnaires**

111 Self-reported questionnaires, comprised 140 questions, were used to gather detailed information
112 covering health, family history, medication, occupational and environmental exposure, lifestyle,
113 psychosocial well-being, socioeconomic status, and other social determinants. These questionnaires had
114 been administered in the SCAPIS trial. During each visit in the S3WP program, a selection of these
115 questions was repeated to update the information from the initial SCAPIS questionnaire. Additionally,
116 participants were asked about any changes in lifestyle factors between visits, such as infections, disease,
117 medication, perceived health, and exercise level.

118 **Anthropometric and clinical measurements**

119 Height was measured to the nearest centimeter without shoes, with participants wearing indoor clothing.
120 Weight was recorded on a calibrated digital scale under the same conditions. BMI was calculated by
121 dividing weight (kg) by the square of height (m). Waist circumference was measured midway between
122 the iliac crest and the lowest rib margin in the left and right mid-axillary lines. Hip circumference was
123 measured at the widest part of the buttocks. Bioimpedance was assessed using the Tanita MC-780MA
124 following the manufacturer's instructions. Systolic and diastolic blood pressure were measured in the
125 supine position after a 5-minute rest using the Omron P10 automatic device. Blood pressure was initially

126 measured in both arms during the first visit, and subsequently in the arm that showed the highest reading.
127 Clinical chemistry and hematology assessments included capillary glucose (Hemocue), plasma glucose,
128 HbA1c, triglycerides, total cholesterol, LDL, HDL, ApoA1, ApoB, ApoA1/B ratio, creatinine, high-
129 sensitive C-reactive protein (hsCRP), ALAT, GGT, urate, cystatin C, vitamin D, TNT, NTproBNP,
130 hemoglobin, and blood cell count. The complete list of the clinical variables can be found in **Additional**
131 **file 2: Table S1**.

132 **Whole genome sequencing**

133 The whole genome-sequencing procedure has been detailed previously by Zhong et al. [33,34]. Briefly,
134 Genomic DNA was sequenced to average 30X coverage on the HiSeq X system (Illumina, paired-end
135 2 × 150 bp). The alignment was performed using BWAmem using GRCh38.p7 as reference genome.
136 Single-nucleotide and insertion/deletion variants were called following the GATK pipeline
137 (https://software.broadinstitute.org/gatk/best-practices; GATK v3.6). BCFtools[35] and PLINK 2.0[36] were
138 used to perform quality control (QC). The exclusion criteria included: (1) removing variants which did
139 not receive the "PASS" tag from GATK; (2) removing variants with minQUAL <30; (3) removing
140 variants/samples that with a genotyping rate < 0.05; (5) removing variants with a low minor allele
141 frequency (MAF) (<5%); (6) removing variants that failed the Hardy–Weinberg equilibrium (HWE)
142 test ($P < 1\times10^{-6}$). In total, 6,691,390 high-quality variants were identified in all samples. Functional
143 annotation of variants was performed using Ensembl Variant Effect Predictor (VEP) v111[37].

144 **Plasma metabolomics and lipidomics profiling**

145 Plasma metabolites and lipids profiling were obtained by gas chromatography-mass spectrometry (GC-
146 MS) and liquid chromatography-mass spectrometry (LC-MS)[29]. Briefly, the metabolites were extracted
147 by using Agilent 1290 Infinity UHPLC-system (reverse phase chromatography) combined with an
148 Agilent 6550 Q-TOF mass spectrometer equipped with an electrospray Jetstream ion source operating
149 in positive and negative ion mode. The *m*/*z* range was 70-1700, and data were collected in centroid
150 mode with an acquisition rate of 4 scans/s. The mass spectrometry files were processed using Profinder
151 B.08.01 (Agilent Technologies Inc., Santa Clara, CA, USA). Peak detection was performed using mass
152 feature extraction. The lipids were extracted following a modified Folch protocol [38]. The data were

153 processed using Batch Targeted Feature Extraction algorithm within MassHunter™ ProFinder version
154 B.08.00 (Agilent Technologies Inc., Santa Clara, CA, USA). In-house databases with exact mass and
155 experimental retention times of lipids were used for identification. The detailed method can be found
156 in Tebani et al.[29]. In total, 456 metabolites were identified in 101 subjects and 173 lipids were measured
157 in 50 subjects.

158 All metabolite concentrations were log2-transformed to approximate a normal distribution. Metabolites
159 with any of the following conditions have been removed: (1) metabolites that failed detection in at least
160 30% of samples; (2) the ratio of maximum and minimum interquartile range (IQR) of metabolite
161 concentrations across four visits > 2; (3) duplicated metabolites. In addition, 5 subjects were removed
162 because they participated in < 4 follow-ups. The filtering process retained a total of 527 unique
163 metabolites for 96 subjects (357 metabolites based on 96 subjects and 170 lipids based on 50 subjects)
164 for the downstream analysis of the study.

165 Metabolite annotation was performed using resources from the Human Metabolomics Database
166 (HMDB) (version 5.0) [39] and relevant literature [4,7–10]. A total of 527 metabolites were categorized into
167 9 main classes and 63 subclasses. Additionally, 11 lipid subclasses were further subdivided into 23
168 secondary lipid subclasses, resulting in the creation of 75 custom terms. These customized terms, along
169 with metabolic pathways curated in the Small Molecule Pathway Database (SMPDB), were used for
170 the enrichment analysis of metabolites. The complete list of the customized terms can be found in
171 **Additional file 2: Table S3.**

172 **Plasma protein profiling**

173 We used a multiplex proximity extension assay (Olink Bioscience, Uppsala Sweden) to measure the
174 relative concentrations of 794 plasma proteins in eleven Olink panels. To minimize inter-run and intra-
175 run variation, the samples were randomized across plates and normalized using both an internal control
176 (extension control) and an inter-plate control; then a pre-determined correction factor was applied to
177 transform the data. The pre-processed data were provided in the arbitrary unit Normalized Protein
178 eXpression (NPX) on a log2 scale. QC procedures were performed at both sample and protein level.
179 Briefly, samples were flagged (did not pass QC) if the incubation control deviated more than a pre-

180 determined value (+/− 0.3) from the median value of all samples on the plate (www.olink.com). To
181 reduce the batch effect between samples run at different times, bridging reference samples from
182 different visits were also run on plates from the different batches. Reference sample normalization based
183 on bridging samples was conducted to minimize technical variation between batches (www.olink.com).
184 After QC, a total of 794 unique proteins for 90 subjects and 6 visits (540 samples) were retained for
185 analysis. The detailed information about plasma protein profiling can be found in previous papers[34,33].
186 Proteins were annotated according to their molecular function, following the Human Protein Atlas v23
187 (https://www.proteinatlas.org/).

188 **Co-expression analysis of plasma metabolites**

189 Before performing co-expression analysis, metabolomics and lipidomics data for 527 metabolites were
190 scaled to zero mean and unit variance. UMAP was applied as an unsupervised clustering modeling
191 method for dimensionality reduction, providing an overview of clustering patterns among samples with
192 similar data profiles. The K Nearest Neighbour Search (KNN) algorithm was implemented to calculate
193 the adjacency matrix using the 'nn2' function from the R package RANN v2.6.1[40], setting the maximum
194 number of nearest neighbors to 20. To calculate the number of shared nearest neighbors (SNN), we
195 employed the 'sNN' function from the R package dbscan v1.1.11[41], considering 5 neighbors for the
196 calculation. R package igraph v1.5.0[42] was used to build the adjacency matrix based on the nearest
197 neighbor results for each metabolite and to identify communities using the 'cluster_louvain' function.
198 In total, 19 clusters were identified from the initial clustering. The mean scaled abundance of
199 metabolites within each of these 19 clusters was then used for a second step of hierarchical clustering.
200 Euclidean distances between the 19 clusters were computed, and similarities were assessed using the
201 ward.D2 method. The hierarchical clustering dendrogram was subsequently divided into 8 distinct
202 groups, resulting in the identification of 8 unique metabolite clusters (**Additional file 2: Table S2**).

203 **Seasonal variation analysis**

204 The seasonal patterns of both metabolites and proteins were analyzed by calculating the amplitude of
205 their temporal expressions. The amplitude was defined as the square root of the sum of the squares of
206 the coefficients of the sine and cosine terms of sampling month from the fitted seasonal model:

207 $$molecular\ abundance\ \sim\ \sin\left(\frac{2\pi \cdot month}{12}\right) + \cos\left(\frac{2\pi \cdot month}{12}\right) + Sex + BMI + Age + (1|individual)\ (1)$$

208 To identify temporally co-expressed metabolites and proteins, Euclidean distances were calculated for
209 those showing significant results associated with sampling month (FDR-adjusted P < 0.05) based on
210 their scaled mean intensity at each month. Clustering analysis was then performed using the 'ward.D2'
211 method in the 'hclust' function from the R 'stats' package. The resulting hierarchical clustering tree was
212 divided into distinct seasonal groups, revealing unique patterns of seasonal variation (**Additional file**
213 **2: Table S5 and Additional file 2: Table S8**).

214 **Genome-wide association analysis of plasma metabolites**

215 For each plasma metabolite, we calculated the coefficients of metabolite intensity for each subject using
216 a linear regression model, with visit included as a covariate. These coefficients served as adjusted
217 metabolite levels for subsequent GWAS analysis. GWAS was conducted using the PLINK v2.0[36],
218 employing a linear regression model that included body mass index (BMI), sex, and age as covariates.
219 To identify independent mQTLs, linkage disequilibrium (LD) $r^2 > 0.1$ with window size 1 Mb was first
220 used to exclude the correlated variants. Given the high correlation among metabolites, we utilized an
221 eigendecomposition method to estimate the effective number of independent metabolites[4]. Out of the
222 527 metabolites, the estimated number of independent metabolites was 23, and this number was used
223 to calculate the Bonferroni threshold for multiple hypothesis testing ($5 \times 10^{-8} / 23 = 2.17 \times 10^{-9}$). For
224 metabolites associated with multiple mQTLs, conditional analysis was performed by re-calculating
225 genetic associations using the lead single-nucleotide polymorphism (SNP) as a covariate. Only
226 associations with a conditional *P*-value < 0.01 were considered to be independent mQTLs. A total of 66
227 significant associations between genetic variants and individual blood metabolite concentrations were
228 identified. Among them, 19 independent metabolite quantitative trait loci (mQTLs) (Linkage
229 Disequilibrium, LD, $r^2 < 0.1$, conditional $P < 0.01$) involving 22 metabolites were identified
230 (**Additional file 2: Table S11**).

231 **Meta-analysis of plasma metabolite GWAS**

232 For the meta-analysis of plasma metabolite GWAS, we included six out of 22 identified genetic-related
233 metabolites with available published GWAS summary results. The GWAS summary data from
234 published studies[4,7] was retrieved via the GWAS Catalog (www.ebi.ac.uk/gwas/, accession date:
235 2023.10), including 3 cohorts: Cooperative Health Research in the Region of Augsburg (KORA, N =
236 1768), TwinsUK (N = 1052) and Canadian Longitudinal Study of Aging (CLSA, N = 8,299). All these
237 three cohorts comprised relatively healthy European individuals. To ensure consistency across datasets,
238 we used LiftOver[43] to convert the genome coordinates to the GRCh38 reference genome. The meta-
239 analysis was performed on these three cohorts along with our study, involving a total of 5.8 million
240 SNPs, using an inverse-variance fixed-effect model using GWAMA v2.2.2[44]. The genome-wide
241 significance threshold for the meta-analysis was set at $P < 8.33\times10^{-9}$, accounting for multiple testing
242 correction (5×10^{-8} / 6).

243 **Experimental validation**

244 ACADS short interfering RNA (siRNA) and negative control siRNA were transfected into 293T cells.
245 Following a 48-hour incubation period, the cells were collected and divided into two equal portions.
246 One portion was lysed and quantified using the Bicinchoninic Acid (BCA) Protein Assay Kit. Equal
247 amounts of protein lysate from each sample were used for immunoblotting to assess the expression
248 levels of the ACADS protein. The immunoblotting results were analyzed to determine the efficacy of
249 ACADS knockdown. The remaining portion of the cells was processed for metabolite analysis.
250 Specifically, the relative content of butyrylcarnitine was measured using a liquid chromatography-
251 quadrupole time-of-flight mass spectrometer (LC-QTOF MS, Agilent #1290-6546). The mass
252 spectrometer was equipped with Agilent Jet-stream source operating in negative and positive ion mode
253 with source parameters set as follow: Nebulizer gas, 45psi; Sheath gas temperature, 325 °C; Sheath gas
254 flow, 10L/min; Dry gas temperature, 280 °C; Dry gas flow, 8L/min; Capillary voltage, 3500v for two
255 ion modes and nozzle voltage, 500v for positive and 1000v for negative mode. The QTOF scan
256 parameters were set as follows: Scan speed, 2 scan/s. Separation of metabolites was achieved in a Waters
257 ACQUITY UPLC BEH Amide column(2.1 mm × 100 mm × 1.7 μm) and guard column (2.1 mm × 5

258 mm × 1.7 μm). Agilent Masshunter profinder 10.0 was used to extract its characteristic m/z 232.1547
259 ion from the total ion chromatogram. Butyrylcarnitine was quantified by peak area. Data analysis was
260 conducted using Agilent MassHunter profinder 10.0 software. The detailed experimental setup are
261 provided in **Supplementary Information**.

262 **Protein-metabolite association analysis, Mendelian randomization, and network analysis**

263 Linear mixed modeling (LMM) was conducted to identify associations between 527 metabolites and
264 794 proteins, with sex, age, and BMI as fixed effects, and subject and visit as random effects. The
265 analysis was performed using the 'lmerTest' package[45], and the Kenward-Roger approximation was
266 applied to calculate *P*-value using the R package 'pbkrtest' v0.5.2[46]. In addition, one-sample MR
267 analysis was performed to test the causal relationships between protein-metabolite pairs identified
268 through LMM (FDR-adjusted $P < 0.05$). This analysis utilized instrumental variable (IV) regression by
269 two-stage least squares (2SLS) using the 'ivreg' function from the R package AER 1.2-10[47], which is
270 based on Sex, age and BMI were included in the regression models as covariates, while the independent
271 pQTLs (genome-wide significance, $P < 5\times10^{-8}$) associated with the protein were used as IVs. SNP
272 would be removed from the IVs if it had more than 5 association across the proteins[13]. The full list of
273 IVs was provided in **Additional file 2: Table S15.**

274 The protein-metabolite association network was constructed by combining both the LMM and MR
275 results. Betweenness centrality score for each node in the network was calculated using the function
276 'betweenness' from the package 'igraph' v1.5.0[42]. Proteins and metabolites with a score > MAD above
277 the respective median were classified as Tier 2, while proteins and metabolites with a score >2×MAD
278 the median were categorized as Tier 1. All significant (FDR-adjusted $P < 0.05$) protein-metabolite pairs
279 identified from the LMM were used to perform a UMAP clustering based on samples without missing
280 values.

281 **Metabolic risk stratification of participants in the study**

282 To evaluate the metabolic risk levels of participants at various study visits, five classical metabolic risk
283 indicators were utilized: body mass index (BMI), high-density lipoprotein (HDL), systolic blood
284 pressure (SBP), fasting glucose (Gluc), and triglycerides (TG). Each measurement was normalized by

285 adjusting for sex-specific effects and then dividing by the standard deviation across all samples. K-
286 means clustering was performed to stratify the samples into two groups (high risk and low risk) using
287 the function 'kmeans' from the R package 'stats' [48]. Additionally, other clinical biochemical markers,
288 including alanine aminotransferase (ALAT), gamma-glutamyltransferase (GGT), urate, troponin T
289 (TNT), and white blood cells (WBC), were normalized in a same way. These markers were then used
290 to test for differential expression levels between the two stratified metabolic risk groups.

291 **Individuals with metabolic diseases in the UK Biobank**

292 The UK Biobank is a large-scale biomedical database and research resource that includes genetic,
293 lifestyle, and health information from half a million UK participants aged 40-69 at baseline[49,50].
294 Participants were enrolled from 2006 to 2010 in 22 recruitment centers across the UK, with follow-up
295 data continuously collected. Proteomic profiling was conducted on blood plasma samples collected
296 during baseline recruitment from a randomized subset of UK Biobank participants. For this study, we
297 focused on Normalized Protein Expression (NPX) data for Tier 1 proteins and extracted metabolic
298 disease diagnoses information (field ID: 41202, ICD 10: E10, E11, E66, E03, E05, E78, M10, E88).
299 Participants with available proteome data for Tier 1 proteins were selected. To validate the predictive
300 power of Tier 1 proteins for various metabolic diseases, we focused on diseases with sufficient case
301 numbers for proteome analysis. Only data from participants diagnosed before baseline recruitment were
302 included, and individuals with multiple diagnoses were excluded. This resulted in the inclusion of type
303 2 diabetes (N = 144), obesity (N = 25), hyperthyroidism (N = 21), and gout (N = 27) for predictive
304 analysis.

305 For robust statistical analysis, NPX values were rank-inverse normal-transformed. Remaining missing
306 values were imputed using the average value calculated across all individuals. Ultimately, the dataset
307 comprised 242 participants in the metabolic disease group and 5,511 in the healthy group.

308 **Identification of individuals who develop obesity in the UK Biobank**

309 To identify individuals at risk of developing obesity in the future, we utilized BMI records (field
310 ID:21001) from the UK Biobank, which included baseline recruitment data collected between 2006 and

311 2010 and three follow-up visits in 2012-2013, 2014+, and 2019+. Participants with a baseline BMI
312 lower than 25 kg/m² were included in the analysis. These individuals were further stratified into two
313 groups: the 'future obese' group, consisting of individuals who recorded a BMI higher than 30 kg/m² in
314 at least one of the three follow-up visits, and the 'control' group, comprising individuals who maintained
315 a BMI lower than 30 kg/m² across all subsequent visits. To ensure data quality and relevance, we filtered
316 the samples based on the availability of proteome data for Tier 1 proteins. This filtering process resulted
317 in the classification of fifteen individuals into the 'future obesity' group and 3,185 individuals into the
318 control group.

319 **Machine learning for predictive tasks**

320 To develop and validate prediction models, the samples were randomly split into training and validation
321 datasets using a 7:3 ratio. For analyses performed on the S3WP data, samples from the same individuals
322 were kept together in either the training or validation group. For the UK Biobank data, balanced datasets
323 were constructed by randomly selecting an equal number of control samples for predicting metabolic
324 diseases. All data were scaled before the prediction analysis. The prediction models were built using
325 the XGBClassifier from the Python library xgboost v2.0.3[51] with "binary:logistic" used as the objective.
326 To address class imbalance, the subsample parameter was set to 0.5, and the scale_pos_weight
327 parameter was adjusted to the ratio of negative and positive samples. The model training and validation
328 procedure was repeated 100 times, each time with a different random split of the data, to account for
329 stochastic variability in the selection of training and validation data. Receiver operating characteristic
330 (ROC) curves were generated and visualized using the R package 'verification' v1.42[52].

331 **Statistical analysis and visualization**

332 Uniform Manifold Approximation and Projection (UMAP) was performed by using the R package
333 umap[53]. Canonical correspondence analysis (CCA) was performed including lifestyle factors,
334 anthropometric and clinical measurements, and visit as constraining variables using the R package
335 vegan v2.6.4[54]. The association between each variable and CCA1 and CCA2 was quantified by the
336 estimated coefficient obtained from univariate linear regression. The mixed model expressed by
337 equation (1) was used to determine the associations between sex, BMI, age, seasonality and metabolite

338 abundance, with metabolite abundance as response, sex, BMI, age, and month of sampling as fixed
339 effects and subject as random effect. All of mixed model analyses were performed using the lmerTest
340 package[45] and Kenward-Roger approximation was applied to calculate *P*-value using the R package
341 pbkrtest v0.5.2[46]. Variance analysis of metabolites and UMAP components was conducted using a linear
342 regression model including significantly associated mQTLs (and pQTLs for UMAP components),
343 clinical measurements, lifestyle parameters, sex, age, and visit as variables. The fraction of explained
344 variability was measured as the Sum of Squares Explained (SSE) and *p*-value was determined using
345 Analysis of Variance (ANOVA) by the built-in R function aov. Pearson correlation was used to estimate
346 the correlation between metabolites and proteins. Kruskal-Walis test and *t*-test were used to compare
347 differences in the levels of metabolites or proteins between groups. Fisher's exact test was used for
348 enrichment analysis of metabolites. FDR was calculated for multiple testing correction by using the
349 function p.adjust, selecting the Benjamini-Hochberg method. FDR-adjusted $P < 0.05$ was considered
350 significant in the analysis.

351 The Sankey plot was generated using the function sankeyNetwork of R package networkD3 v0.4[55]. The
352 heatmap was generated using the R package pheatmap v1.0.12[56]. Networks were created using the R
353 package igraph v1.5.0[42]. Chord diagrams were generated using the R packages circlize[57]. Spider plots
354 were generated using the package ggradar v0.2[84]. The package ggalluvial v0.12.5[58] was used to show
355 the group of the samples from the same individual across the six visits. All the other visualizations were
356 performed using the ggplot2[59] R package. All of the data analysis and visualization was performed using
357 the R project[60].

358 # Results

359 **Longitudinal analysis of human metabolic profiles in a wellness study**

360 To systematically investigate the human metabolic profiles over time, we performed a comprehensive
361 integrative multi-omics analysis of 101 participants in the Swedish SciLifeLab SCAPIS Wellness
362 Profiling (S3WP) program over two years [29]. Whole-genome sequencing was performed at baseline for
363 all participants. Extensive phenotyping of the individuals was conducted every three months in the first

364 year and at approximately a 6-month interval in the second year, which included plasma metabolome
365 and lipidome profiling, proteome profiling, clinical measurements, and detailed lifestyle questionnaires
366 covering physical activity, mental health, substance intake, and other environmental factors, alongside
367 blood sample collection, to capture seasonal fluctuations and provide a robust temporal perspective (**Fig.**
368 **1a and Additional file 2: Table S1**). Using a combination of GC-MS and LC-MS technologies, we
369 identified a total of 527 metabolites in the study. These metabolites were classified into nine main
370 classes, covering a wide range of lipids (n = 335, 63.6%), amino acids (n = 77, 14.6%), xenobiotics (n
371 = 37, 7.0%), peptides (n = 17, 3.2%), carbohydrates (n = 20, 3.8%), cofactors and vitamins (n = 16,
372 3.0%), nucleotides (n = 14, 2.7%), energy (n =7, 1.3%), and other metabolites (n = 4, 0.8%). The
373 metabolites were further categorized into 63 subclasses based on their functions and biochemical
374 characteristics (**Fig. 1a and Additional file 2: Table S2, see Methods for more details**).

375 To explore the co-expression patterns of these identified metabolites, we conducted a clustering analysis
376 applying K-nearest neighbor (KNN), shared nearest neighbor (SNN) and Louvain algorithms and
377 revealed that the 527 measured metabolites could be classified into eight major clusters (**Fig. 1b-c,**
378 **Additional file 1: Fig. 1 and Additional file 2: Table S2**). Functional enrichment analysis based on
379 customized class and pathway terms was further performed for each cluster to identify shared pathways
380 among groups of co-expressed metabolites (**Fig. 1d and Additional file 2: Table S3**). Specifically,
381 cluster 1 showed a co-regulation of pathways involved in fatty acid metabolism, including steroids and
382 their derivatives, as well as monoglycerides. Cluster 2 mainly included metabolites related to the
383 metabolism of dietary components such as caffeine and benzoates. Cluster 3 included pathways central
384 to the urea cycle, specifically the arginine and proline metabolism. It also involved the metabolism of
385 amino acids like methionine, cysteine, glycine, serine, and theronine, which are crucial for nitrogen
386 balance and protein turnover[61]. Cluster 4 exhibited a co-expression similar to Cluster 3, featured by
387 metabolites like dipeptides as well as the metabolisms of arginine, aspartate, and gamma-glutamyl
388 amino acids, which are mainly involved in protein synthesis and amino acid recycling[62]. Cluster 5
389 mainly consisted of metabolites essential for the cell membranes composition and signaling, including
390 sphingomyelin, ceramide, and phosphatidylcholine[63]. Cluster 6 showed the interconnected pathways of

391 glycolysis, gluconeogenesis, and sugar metabolisms, including the metabolism of fructose, mannose,
392 and galactose. Cluster 7 included metabolites related to energy storage and mobilization, such as
393 triglycerides and diglycerides[64]. Cluster 8 comprises lyso-phosphatidylcholine, lyso-
394 phosphatidylethanolamine, and phosphatidylcholine, key components involved in cell membrane
395 remodeling[65].

396 **Individual and seasonal variations in plasma metabolome profiles**

397 We assessed the variability in the expression of each metabolite over time by analyzing both inter-individual
398 and intra-individual variations, calculated using the coefficient of variance (CV; **Fig. 2a and Additional file**
399 **2: Table S4**). Notably, our analysis revealed that the variability between individuals for each measured
400 metabolite was greater than the variability observed within the same individual, with ratios of inter-
401 individual to intra-individual CV ranging from 1.09 to 8.86. Among these metabolites, pyrrole-2-carboxylic
402 acid and picolinic acid showed the most significant differences between individuals (**Fig. 2a**). This suggests
403 that, despite the fluctuations in each person's metabolic profile over time due to various environmental
404 factors, each individual maintained a distinct metabolomic signature.

405 Interestingly, some metabolites showed seasonal patterns which partially contributed to the intra-individual
406 variations. To explore the seasonal influences on metabolite variability and identify potential seasonal
407 patterns, we performed an association analysis between metabolite levels and the month of sampling, with
408 sex, age and BMI considered as covariates. A total of 121 metabolites showed clear associations with the
409 month of sampling, with amplitudes ranging from 0.016 to 0.541 (**Fig. 2b and Additional file 2: Table S5**).
410 Hierarchical clustering of these metabolites further showed four distinct seasonal patterns: extremely low
411 levels from January to March (Cluster M1, n = 18); relatively low levels during the winter months (Cluster
412 M2, n = 18); relatively high levels during winter (Cluster M3, n = 49); extremely high levels in December
413 (Cluster M4, n = 36) (**Fig. 2c-g and Additional file 2: Table S6**). The metabolites in Cluster M1, exhibiting
414 the lowest levels from January to March, were enriched in carbohydrate metabolism pathways (**Fig. 2h and**
415 **Additional file 2: Table S7**). As an example, fructose reached its lowest levels in January and February
416 (**Additional file 1: Fig. 2a**). This could reflect a post-holiday shift to baseline dietary habits or a reduction
417 in the consumption of sugars. Conversely, the elevation of energy-related pathways in Cluster M4 during
418 December may indicate an increased caloric intake during the festive period or an adaptive physiological

419 response to colder temperatures. Metabolites in Cluster M2, with relatively low levels in winter, were
420 enriched in pathways associated with NAD^+ signaling, nicotinate and nicotinamide metabolism, purine
421 metabolism, and phosphatidylethanolamine biosynthesis (**Fig. 2h**). This could reflect a reduced requirement
422 for or availability of these pathways' end products during the winter, possibly due to changes in diet, reduced
423 exposure to sunlight affecting vitamin D synthesis, which in turn affects NAD^+ synthesis [66]. Interestingly,
424 the seasonal pattern of vitamin D closely correlated with the metabolites in Cluster M2 (Pearson $P = 0.04827$,
425 **Fig. 2i**). In contrast, Cluster M3 metabolites, which were relatively high during winter, were associated with
426 amino acid metabolism, specifically glycine and serine metabolism, as well as pathways involved in
427 ammonia recycling and the metabolism of methionine and homocysteine (**Fig. 2h**). For instance, the highest
428 level of cysteine was observed during winter (**Additional file 1: Fig. 2b**). These increased levels of amino
429 acid metabolism could suggest a shift in fuel utilization towards amino acid catabolism for energy production
430 and could also be associated with lower levels of physical activity as reported by Pedersen EB, *et al*[67].
431 Interestingly, the energy metabolism-related fatty acid succinylcarnitine in Cluster M3, which is involved in
432 carnitine synthesis and utilization pathway, also showed a significantly high inter-individual variation,
433 indicating varying levels of energy metabolism among individuals (**Fig. 2j**).

434 We further analyzed the seasonal variations of plasma proteins and found that some plasma proteins also
435 exhibited seasonal patterns, with two opposite seasonal clusters observed: Cluster P1, with low levels during
436 the colder season (Cluster P1, n = 51), and Cluster P2, with relatively low expression levels during the
437 warmer months (Cluster P2, n = 312) (**Additional file 1: Fig. 2c-e and Additional file 2: Table S8**). As an
438 example, 46 proteins in Cluster P2 were found to closely correlate with the seasonal patterns of metabolites
439 in Cluster M3. These proteins primarily function in amino acid, glycan, and fatty acid metabolism.
440 Specifically, angiopoietin-like protein 4 (*ANGPTL4*), which regulates lipoprotein lipase and has been found
441 to be influenced by dietary fatty acids in both human muscle[68] and mice heart[69], showed associations with a
442 group of fatty acids, such as cis-4-decenoylcarnitine and laurylcarnitine (**Additional file 1: Fig. 2f and 2g**).
443 Along with these fatty acids, ANGPTL4 exhibited relatively lower expression levels from June to September
444 (**Additional file 1: Fig. 2h**). The associations between proteins and metabolites will be described in more
445 depth below.

446 **Sex- and BMI-related divergences in plasma metabolite levels**

447 The associations between plasma metabolite concentrations, lifestyle factors and clinical measurements were
448 analyzed using canonical correspondence analysis (CCA) that incorporated all 527 metabolites, 13 lifestyle
449 variables, and 43 clinical chemistry and anthropometric variables across visits. Regression analysis of the
450 two CCA components showed that CCA1 was mainly associated with BMI and lipid profiles, whereas CCA2
451 was more closely related to sex, body composition (muscle and fat percentage), hemoglobin, and urate.
452 Notably, a clear divergence between male and female samples was observed, emphasizing sex as a significant
453 factor influencing plasma metabolomic levels (**Fig. 3a**). The associations between metabolites and sex were
454 visualized in a volcano plot (**Fig. 3b and Additional file 2: Table S9**). Among the 119 metabolites that
455 showed significant sex differences, 35 were found to be elevated in females and 84 were more abundant in
456 males (**Fig. 3b**). In particular, the peptide gamma-glutamylleucine exhibited higher levels in males (**Fig. 3c**)
457 and has been found to be associated with elevated cardio-metabolic risks[70]. Additionally, 86 BMI-related
458 metabolites were identified (**Fig. 3d and Additional file 2: Table S10**), with glutamic acid showing the
459 strongest association (**Fig. 3e**), which aligns with previous reports[71]. Furthermore, the ratio of glutamic acid
460 to other amino acids, such as lysine, ornithine, and hydroxyproline, have been reported as promising
461 biomarkers for identifying metabolically healthy obese individuals[71]. Interestingly, lifestyle factors such as
462 physical activity, stress, and smoking were found to correlate with metabolite levels and show collinearity
463 with sex. In general, the stress levels in females were higher than in males, which was also significantly
464 associated with the elevation of the stress hormone corticosteroid[72]. On the other hands, a higher incidence
465 of smoking among males was associated with the alterations in several metabolites, such as glutamine, which
466 plays a central role in cellular metabolism and function, highlighting the influence of lifestyle factors on
467 metabolic health.

468 **Genome-wide association analysis of the plasma metabolite profile**

469 To investigate the genetic influence on inter-individual differences in plasma metabolite concentration,
470 a GWAS was performed based on individual variation coefficients for 527 plasma metabolites and 6.7
471 million common genetic variants (minor allele frequency, MAF > 0.05) identified through whole-
472 genome sequencing. A total of 66 significant associations between genetic variants and individual blood
473 metabolite concentrations were identified ($P < 2.17 \times 10^{-9}$, conventional P of 5×10^{-8} adjusted for the

474 number of independent metabolites [4]). Among them, 19 independent metabolite quantitative trait loci
475 (mQTLs) (Linkage Disequilibrium, LD, $r^2 < 0.1$, conditional $P < 0.01$) involving 22 metabolites were
476 identified (**Fig. 4a and Additional file 2: Table S11**). Of 19 mQTLs, 4 were pleiotropic genetic variants
477 associated with multiple metabolites. Of these metabolites, 45% were lipids (n = 10) (**Fig. 4a-b**). Out
478 of the 22 genetically associated metabolites in our study, six have been previously analyzed in other
479 GWAS studies[4,7]. To validate the associations between these metabolites and genetic variants, a meta-
480 GWAS analysis was conducted for these six metabolites. Most of the genetic loci (8 out of 11) identified
481 from meta-analysis showed the same direction of effects as in our study (**Additional file 2: Table S12**).
482 Among these, the association between the genetic variant (rs34673751) from Acyl-CoA dehydrogenase
483 short chain (*ACADS*) and butyrylcarnitine was the most significant in the meta-analysis. The *ACADS*
484 gene encodes the enzyme short-chain acyl-CoA dehydrogenase (SCAD), which is essential for
485 mitochondrial fatty acid beta-oxidation, while butyrylcarnitine is a short-chain acylcarnitine involved
486 in fatty acid transport and energy metabolism. Our longitudinal analysis further demonstrated that
487 individuals carrying A allele at rs34673751 exhibited stable higher blood butyrylcarnitine levels.
488 Moreover, heterozygous individuals for the protein variant presented intermediate levels of blood
489 butyrylcarnitine compared to the homozygous groups **(Fig. 4c-e**). To experimentally validate the
490 association between *ACADS* and butyrylcarnitine, we knocked down the expression of *ACADS* in 293T
491 cell lines using siRNA. Subsequent metabolite analysis revealed that silencing the *ACADS* gene
492 increased the levels of butyrylcarnitine in these cells **(Fig. 4f-g**), providing direct evidence of *ACADS*'s
493 role in the regulation of butyrylcarnitine levels.

494 Another notable example of the identified mQTLs is the association between metabolite 4-androsten-
495 3alpha,17alpha-diol monosulfate (2), a sulfated steroid and a derivative of androstenediol, and the gene
496 cytochrome P450 family 3 subfamily A member 7 (*CYP3A7*). (**Fig. 4h**). The highest association was
497 found for the variant rs45446698, located upstream of the *CYP3A7* gene. Individuals carrying a TT
498 homozygote had higher and more stable levels of 4-androsten-3alpha,17alpha-diol monosulfate (2) than
499 individuals carrying a TG heterozygote (**Fig. 4i-j**).

500 **Quantification of genetic and non-genetic effects on plasma metabolite levels**

501 To quantify the influence of genetics, lifestyle, and physiological conditions on metabolite variability,
502 we applied a linear multivariate regression model to each metabolite. This model included all 19 mQTLs,
503 13 lifestyle factors, 43 anthropometric and clinical chemistry parameters, and visit. In the analysis, the
504 genetic variants were combined as "genetic component", all the lifestyle-related factors were combined
505 as "lifestyle component", and all anthropometric and clinical chemistry variables were categorized into
506 13 clinical classes. A summary of the analysis across all 527 analyzed plasma metabolites (**Fig. 5a and**
507 **Additional file 2: Table S13**) showed that the influence of genetics, lifestyle, and physiological
508 conditions on plasma metabolite level varied considerably. Genetics emerged as one of the important
509 factors; out of the 22 metabolites with at least one significant genetic association, 5 metabolites had a
510 genetic contribution greater than 20% (**Fig. 5b**). The metabolite most affected by genetics was 1,3-
511 Dimethylurate, which is formed from caffeine and can be used as an indicator of caffeine metabolism
512 [73], with 30% of its blood level variance explained by genetic variants. Besides genetics, 469 metabolites
513 were influenced by various clinical factors, with a total contribution greater than 20%. Consistent with
514 the CCA analysis (**Fig. 3a**), body composition and lipid profiles showed the most significant
515 associations with plasma metabolite levels, with 69 metabolites associated with each of them. In
516 addition, 54 metabolites were associated with urate levels, 48 with kidney function, 36 with glucose
517 homeostasis, 18 with liver function, 17 with heart function, 15 with leukocytes, 6 with the acute phase
518 response, and 28 with other clinical parameters. The top 25 most significant metabolites associated with
519 clinical components were highlighted in **Fig. 5c.** As an example, a significant association was observed
520 between body composition and pyroglutamylvaline, aligning with previous study that found
521 pyroglutamylvaline to be positively associated with leg muscle[74]. Additionally, multiple metabolites
522 have been identified as being associated with immune cell and red cell populations, as well as
523 inflammatory biomarkers like C-reactive protein (CRP) (**Fig. 5c and Additional file 2: Table S13**).
524 These results indicated the intricate crosstalk between metabolism, immune response, and
525 hematopoiesis.

526 Furthermore, we identified 39 metabolites associated with various lifestyle factors, with 9 showing an
527 influence from lifestyle factors greater than 20% (**Additional file 2: Table S13**). These lifestyle-related
528 metabolites included 15 associated with smoking, 8 with changes in housing, 4 with physical activity,
529 4 with stress, and 9 with other lifestyle factors. The top 25 most significant metabolites associated with
530 lifestyle factors are listed in **Fig. 5d**. Notably, smoking had the most prominent influence on blood
531 metabolite levels. Among the smoking associated metabolites, glutamine, the most abundant amino acid
532 in the body and considered conditionally essential for critical illness and injury[75,76], was negatively
533 associated with smoking, along with factors such as 3-pyridinol, an intermediate product in nicotine
534 degradation[77] (**Additional file 2: Table S13**).

535 **Individual metabolite-protein profiles in human plasma**

536 To investigate the co-expression patterns of plasma metabolites and proteins, we applied linear mixed
537 modeling (LMM) to 527 metabolites and 794 proteins, adjusting for cofounders including subject, visit,
538 sex, age, and BMI. The analysis revealed 5,649 significant protein-metabolite pairs, involving 479
539 metabolites and 625 proteins, each characterized by a correlation with a false discovery rate (FDR)
540 adjusted *P* of less than 0.05 (**Additional file 2: Table S14**). Among these significant associations, 459
541 involving 121 metabolites and 257 proteins (48.93% of the overlapping metabolite-protein associations)
542 aligned with previous findings from Benson MD, et al.[78], despite differences in molecular measurement
543 platforms. In **Fig. 6a** we present the 200 most significant protein-metabolite associations to illustrate
544 the complex interplay within the protein-metabolite network. Multiple important hormones, enzymes,
545 receptors and cytokines, such as glucagon (GCG), lipoprotein lipase (LPL), natriuretic peptide (NPPC),
546 and interleukin 10 (IL10), have been identified as hub proteins in the network, highlighting their broad
547 regulatory roles in human metabolism. Most of these protein-metabolite associations were connected
548 to lifestyle and physiological conditions. As an example, we found a co-regulation between leptin (LEP)
549 and aceturic acid **(Fig. 6b).** LEP, a hormone secreted by adipose tissue, plays an important role in
550 regulating hunger and energy balance[79], with higher concentrations observed in females[80]. Aceturic acid,
551 also known as N-acetylglycine, is a derivative of the amino acid glycine and has been reported to

552 modulate weight and associated adipose tissue immunity [81]. Our findings suggested a significant
553 interaction between LEP and aceturic acid with gender stratification.

554 Subsequent Mendelian Randomization (MR) analyses were conducted to investigate potential genetic
555 drivers of causality between plasma proteins and metabolites. A total of 87 putative causal associations
556 were identified between 38 proteins and 61 metabolites (FDR-adjusted $P < 0.05$, **Additional file 1: Fig.**
557 **3a, Additional file 2: Table S15**). As an example, we detected a significant MR association between
558 MDGA1, a cell surface glycoprotein involved in cell adhesion, migration, axon guidance, and
559 neurodevelopment[82–84], and 1-Arachidonoylglycerol (1-AG) (**Fig. 6c**), a stable regioisomer of the
560 endocannabinoid 2-AG engaged in physiological functions such as emotion, cognition, and
561 neuroinflammation[85,86]. Our analyses showed that the cis instrumental variable (rs9349050, **Fig. 6d**) for
562 the MDGA1 protein consistently differentiated both MDGA1 and 1-AG levels in individuals carrying
563 different genotypes (**Additional file 1: Fig. 3b-c**). This stable and positive association between
564 MDGA1 and 1-AG indicated a potential genetic basis for the co-regulation of proteins and metabolites
565 in the nervous system.

566 Using Uniform Manifold Approximation and Projection (UMAP), we clustered the individual
567 molecular profiles based on the integrated metabolite-protein network. We noted that each individual
568 possessed a unique and stable protein-metabolic profile (**Fig. 6e**). Regression analysis of the two UMAP
569 components (**Fig. 6f-g**) revealed that UMAP1 was most significantly associated with genetic factors,
570 followed by kidney function, lipid profile, body composition and erythrocytes. UMAP2 showed
571 significant associations with body composition, blood pressure, genetics, and erythrocytes. Additionally,
572 immune response, vitamin D, urate levels, liver functions, glucose homeostasis were moderately
573 associated with the metabolite-protein profiles. Lifestyle factors such as stress, drug intake, smoking,
574 and physical activity also exhibited minor influences on these profiles.

575 To identify key proteins and metabolites with the highest connectivity of the protein-metabolite network,
576 we quantified their importance using the centrality betweenness score and categorized them into three
577 tiers based on their deviation from the median level, measured in median absolute deviations (MAD).
578 These categories include Tier 1, high importance (beyond two MADs); Tier 2, moderate importance

579 (beyond one MAD); and Other: low importance (within one MAD). (**Fig 6 h-i**). Notably, ANGPTL4
580 and LEP were the top two proteins with the highest scores (**Fig. 6j**). *ANGPTL4* has been reported as a
581 key regulator in lipid metabolism, primarily by inhibiting the activity of lipoprotein lipase (*LPL)*[87], and
582 also involved in angiogenesis, vascular permeability, and inflammation processes. In our analysis, we
583 revealed that ANGPTL4 was associated with a broad spectrum of metabolites, involving those related
584 to lipid and glucose metabolism, tissue functions, and immune responses **(Additional file 1: Fig. 3d).**
585 LEP, which is a well-known hormone, has been shown in recent studies to reflect systemic alterations
586 of the human metabolome[88,89]. In our analysis, we observed that LEP was associated with a spectrum
587 of metabolites related to blood pressure and glucose homeostasis, as well as stress **(Additional file 1:**
588 **Fig. 3d)**. On the other hand, N-Acetylaspartate (NAA), one of the most abundant metabolites in the
589 mammalian brain, and 3-Hydroxyhippurate, a microbial aromatic acid metabolite derived from dietary
590 polyphenols and flavonoids found in normal human urine, were identified as high-importance
591 metabolites through network analysis and found to be associated with kidney function in the study **(Fig.**
592 **6k, Additional file 2: Table S13**).

593 **Variability of protein-metabolite profiles and the associations with metabolic health**

594 To investigate the associations between protein-metabolite profile variability and metabolic health, we
595 stratified the analyzed samples into two risk groups (high-risk group and low-risk group) based on the
596 clustering patterns of five key indicators of metabolic syndrome: high density lipoprotein (HDL), body
597 mass index (BMI), systolic blood pressure (SBP), triglycerides (TG) and fasting glucose (Gluc)[90]. The
598 high-risk group was characterized by increased levels of BMI, SBP, TG, and Gluc, alongside decreased
599 levels of HDL, in comparison with the low-risk group **(Fig. 7a**). We then explored the differences in
600 clinical chemistry measurements between these two groups. We found significant higher levels of two
601 liver function biomarkers (alanine aminotransferase, ALAT; gamma glutamyltransferase, GGT), one
602 kidney function biomarker (urate), one heart function biomarker (troponin T, TNT), and one immune
603 biomarker (white blood cells count, WBC) in the high-risk group, indicating an increased susceptibility
604 to cardiometabolic diseases **(Fig. 7b**).

605 Predictive modeling of the metabolic risk of the analyzed samples was conducted using proteins and
606 metabolites. Interestingly, we found that the predictive power for risk groups, based on a combination
607 of all proteins and metabolites, to be comparable to that based on Tier 1 proteins (n = 13) and metabolites
608 (n = 14) alone, as well as models based on only proteins (**Fig. 7c,d**). This highlighted the potential
609 importance of Tier 1 proteins and metabolites for metabolic risk assessments. In addition, proteins
610 contributed more significantly to metabolic risk prediction than metabolites, with metabolites providing
611 only marginal additional predictive value. Remarkably, the predictive power of Tier 1 proteins alone
612 approached that of the full protein model (**Fig. 7c,d**), while metabolites demonstrated considerably
613 lower predictive power compared to proteins (**Fig. 7c,d**). The importance of Tier 1 proteins and
614 metabolites in relation to metabolic risk was quantified using a linear regression model to estimate the
615 impact coefficients (**Fig. 7e,f**). We further examined the expressions levels of the 13 Tier 1 proteins in
616 individuals with metabolic diseases, including obesity, type 2 diabetes (T2D), gout or hyperthyroidism,
617 compared to healthy individuals using data from the UK Biobank[49]. Our analysis revealed that the
618 expression levels of all Tier 1 proteins were significantly different ($P<0.05$) between healthy individuals
619 and those diagnosed with any of these metabolic diseases **(Fig. 7g, Additional file 1: Fig. 4)**.
620 Furthermore, the expression patterns of these 13 Tier 1 proteins varied significantly across different
621 metabolic diseases, indicating their potential use as diagnostic biomarkers for various metabolic
622 conditions. Moreover, we assessed the predictive power of Tier 1 proteins for these metabolic diseases,
623 resulting in average AUCs ranging from 0.643 and 0.878 across different diseases (**Fig. 7h**).

624 Next, we examined the stability of the risk levels of participants throughout the two-year study. In
625 general, the metabolic health status of most participants (70 out of 101) remained consistent, with 39
626 categorized within the high-risk group and 31 within the low-risk group at every visit (**Fig. 7i**). A notable
627 exceptional case was participant W0010, who experienced a significant weight reduction from 120 kg
628 during the third visit to 104.7 kg by the fourth visit (**Fig. 7j**). This remarkable change caused a shift
629 from the high-risk group in the initial three visits to the low-risk group in the subsequent three
630 assessments. Focusing on the Tier 1 proteins, we observed a significant decrease in their levels from
631 the third to the fourth visit (**Fig.7k**). However, between the fourth and sixth visits, protein levels

632 reversed despite no significant change in BMI (**Fig. 7k**), suggesting alterations in the individual's
633 underlying metabolism at the molecular level. Additionally, we found that nearly half of the Tier 1
634 proteins (6 / 13) displayed significantly different levels between lean (BMI < 25) and obese (BMI > 30)
635 groups (**Additional file 1: Fig. 5**). We further predicted future obesity in individuals with a baseline
636 BMI lower than 25 in the UK Biobank using the 13 Tier 1 protein expressions. The results showed that
637 participants who later developed obesity (BMI > 30) already exhibited a distinct profile of Tier 1
638 proteins at baseline compared to those who maintained a BMI lower than 30 throughout the study period
639 (**Additional file 1: Fig. 6a, b**). Predictive models demonstrated that baseline expression levels of Tier
640 1 proteins could predict future obesity with an average AUC of 0.773 with a 95% confidence interval
641 of 0.739-0.806 (**Fig. 7l**).

642 # Discussion

643 In this study, we have performed a longitudinal multi-omics analysis on a group of clinically healthy
644 participants aged 55 to 65 over two years to explore how genetics, lifestyle and physiological conditions
645 affect individual metabolic profiles. We systematically examined the abundances and dynamics of 527
646 blood metabolites, which were categorized into nine major classes: lipids, amino acids, xenobiotics,
647 peptides, carbohydrates, cofactors and vitamins, nucleotides, energy, and others. These metabolites
648 were analyzed alongside their co-regulations with 794 proteins. By integrating whole-genome
649 sequencing and extensive phenotyping data collected concurrently at each sampling time point, our
650 results revealed an intricate interplay between genetic predispositions and environmental factors in
651 shaping individual metabolic profiles.

652 One unique aspect of our study is the focus on the temporal dynamics of individual metabolic profiles.
653 We identified eight co-expressed metabolite clusters based on longitudinal data and linked them to
654 various metabolic pathways that are susceptible to both internal and external modulators, such as energy
655 mobilization and dietary intake. By analyzing intra-individual metabolite variation over time, we
656 observed four distinct seasonal patterns of plasma metabolites, with more fluctuations or extreme
657 concentrations during the summer and winter. These seasonal fluctuations of metabolites might reflect
658 changes in physical activity [67], diet [91], and metabolic rate [92], which are closely related to the season and

659 might be regulated by seasonal gene expressions in multiple tissue types, including adipose tissue, brain,
660 and gonadal tissue [93,94]. Similar seasonal variations were observed in the proteomics profiling,
661 suggesting a coordinated seasonal influence on both metabolite and protein levels.

662 In general, our analysis revealed higher inter-individual variations than intra-individual variations in
663 plasma metabolite levels. By integrating whole-genome sequencing, we identified significant
664 associations between genetic variants and blood metabolite levels (mQTLs). Numerous mQTLs have
665 been identified within various populations[8–13,95], and in this study, we used individual coefficients
666 obtained from longitudinal data to better associate metabolite levels with genetic factors. Considering
667 the significant seasonal variations observed in metabolite levels, this approach allows for more accurate
668 quantification of individual metabolite levels for mQTL identification. Our findings indicated that many
669 plasma metabolite levels during adult life were genetically predetermined at birth and remained stable
670 within a range of dynamics under healthy conditions. Additionally, our results showed that lifestyle and
671 clinical factors also significantly contributed to the variability in blood metabolite levels. Notably, 89%
672 of (469 out of 527) metabolites exhibited at least a 20% variability attributable to lifestyle or clinical
673 factors, indicating a substantial influence from lifestyle and physiological conditions on human
674 metabolism. Among these, body composition and smoking were the top physiological and lifestyle
675 factors influencing blood metabolite levels.

676 Proteins, as essential regulators and executors of metabolic processes, are critical components of human
677 metabolic profiles, making their analysis essential for a comprehensive understanding of human
678 metabolism. By integrating longitudinal metabolomics and proteomics data from the same individuals,
679 we established a protein-metabolite co-expression network and found that each individual possessed a
680 unique and stable protein-metabolic profile over time. This stability of individuals' protein-metabolite
681 profiles suggested that, despite the changes in environment, there is an inherent individuality to
682 metabolic regulation. Our analysis showed that genetic factors were the most significant contributors to
683 these profiles, with additional moderate influences from physiological conditions such as kidney
684 function, blood pressure, and body compositions. Moreover, lifestyle factors like stress, smoking, and
685 drug intake also had considerable impacts.

686 Furthermore, we identified key signature proteins and metabolites that characterize individual protein-
687 metabolic profiles and assessed the predictive power of the most important Tier 1 proteins and
688 metabolites for identifying individuals at high metabolic risk. Remarkably, the predictive performance
689 of these Tier 1 biomarkers was comparable to that of the full set of proteins and metabolites,
690 underscoring their potential utility in metabolic health monitoring. This finding also revealed a superior
691 predictive power of proteins over metabolites. This is likely because proteins are directly involved in
692 essential metabolic processes, function as signaling molecules and regulators, and generally exhibit
693 greater stability and consistency over time. In our previous report, we also showed that plasma proteome
694 exhibited most of the effects from clinical data[34,33]. We further validated this panel of 13 Tier 1 proteins
695 in large-scale population data from the UK Biobank for the prediction of metabolic diseases. These
696 biomarkers showed significant potential in diagnosing metabolic diseases. Although, all of the 13
697 proteins were elevated in various metabolic diseases, they exhibited different patterns in different
698 metabolic abnormalities. Interestingly, we observed that the levels of the 13 proteins in an obese
699 individual in the S3WP study initially decreased following weight loss but subsequently started to revert
700 to the initial levels, despite a stable BMI during the study period. In the UK Biobank, we also noted that
701 individuals who eventually became obese already exhibited an altered profile of Tier 1 proteins at a
702 normal BMI and at baseline. These observations suggest that fluctuations in the proteome may precede
703 BMI changes, highlighting their potential value in weight management strategies. However, it should
704 be noted that more comprehensive analyses in large disease cohorts of these plasma proteins and
705 metabolites must be performed to validate their use as clinical biomarkers. Another limitation of this
706 study is the relatively small cohort size, which may not capture the full spectrum of individual metabolic
707 variability across diverse populations. Thus, further validation and generalization of the findings in
708 larger, more diverse cohorts and in clinical settings are necessary.

709 **Conclusions**

710 In summary, our study provides a comprehensive longitudinal analysis on how genetics, lifestyle, and
711 physiological factors influence the human metabolic profiles. Our results demonstrated the dynamic
712 interplay between genetic predispositions and environmental factors, including seasonal variations,

713 lifestyle, and physiological changes. By integrating proteomics and metabolomics data, we established
714 a detailed protein-metabolite network and identified key molecular signatures that enhanced metabolic
715 disease diagnostics and risk assessments. These findings offer promising avenues for improving
716 metabolic health monitoring and developing future targeted interventions based on an individual's
717 unique metabolic profile.

718 Abbreviations

719 **1-AG:** 1-Arachidonoylglycerol
720 **ACADS:** Acyl-CoA dehydrogenase short chain
721 **ALAT:** Alanine aminotransferase
722 **ANGPTL4:** Angiopoietin-like protein 4
723 **ANOVA:** Analysis of Variance
724 **ApoA1:** Apolipoprotein A1
725 **ApoB:** Apolipoprotein B
726 **AUC:** Area under curve
727 **BMI:** Body mass index
728 **CCA:** Canonical correspondence analysis
729 **CRP:** C-reactive protein
730 **CV:** Coefficient of variance
731 **CYP3A7:** Cytochrome P450 family 3 subfamily A member 7
732 **FDR:** False discovery rate
733 **GCG:** Glucagon
734 **GC-MS:** Gas chromatography-mass spectrometry
735 **GGT:** Gamma glutamyltransferase
736 **Gluc:** Fasting glucose
737 **GWAS:** Genome-wide association studies
738 **HDL:** High density lipoprotein
739 **HMDB:** Human Metabolomics Database

740 **IL10:** Interleukin 10

741 **IV:** Instrumental variable

742 **KNN:** K-nearest neighbor

743 **LC-MS:** Liquid chromatography-mass spectrometry

744 **LD:** Linkage Disequilibrium

745 **LDL:** Low density lipoprotein

746 **LEP:** Leptin

747 **LMM:** Linear mixed modeling

748 **LPL:** Lipoprotein lipase

749 **MAD:** Median absolute deviation

750 **MAF:** Minor allele frequency

751 **MDGA1:** MAM domain containing glycosylphosphatidylinositol anchor 1

752 **mQTL:** Metabolite quantitative trait loci

753 **MR:** Mendelian randomization

754 **NAD+:** Nicotinamide adenine dinucleotide+

755 **NPPC:** Natriuretic peptide

756 **NPX:** Normalized Protein eXpression

757 **NTproBNP:** N-Terminal pro-brain natriuretic peptide

758 **pQTL:** Protein quantitative trait locus

759 **QC:** Quality control

760 **Q-TOF:** Quadrupole Time-of-Flight

761 **ROC:** Receiver operating characteristic

762 **S3WP:** Swedish SciLifeLab SCAPIS Wellness Profiling

763 **SBP:** Systolic blood pressure

764 **SCAD:** Short-chain acyl-CoA dehydrogenase

765 **SCAPIS:** Swedish CArdioPulmonary bioImage Study

766 **siRNA:** short interfering RNA

767 **SMPDB:** Small Molecule Pathway Database

SNN: Shared nearest neighbor

SNP: Single-nucleotide polymorphism

T2D: Type 2 diabetes

TG: Triglyceride

TNT: Troponin T

UMAP: Uniform manifold approximation and projection

WBC: White blood cells count

Declarations

Ethics approval and consent to participate

The Swedish SciLifeLab SCAPIS Wellness Profiling (S3WP) study has been approved by the Ethical Review Board of Göteborg, Sweden (registration number 407-15), and all participants provided written informed consent. The study protocol adheres to the ethical guidelines outlined in the 1975 Declaration of Helsinki.

Consent for publication

Not applicable.

Availability of data and materials

This study utilized participant-level datasets that have been securely deposited at the Swedish National Data Service (SND), a repository certified by the Core Trust Seal (URL: https://snd.gu.se/). The GC and LC-MS datasets are available as part of the full SW3P Wellness multi-omics dataset with the doi 10.5878/rdys-mz27. In compliance with patient consent and confidentiality agreements, these datasets are accessible for validation purposes only. Requests for access can be directed to SND via email (snd@snd.gu.se). The evaluation of such requests will be conducted in accordance with relevant Swedish legislation. Additionally, for inquiries specifically on research within the scope of the S3WP program, interested parties are encouraged to contact the corresponding author directly. The code can be made available upon request to the corresponding author.

794 **Competing interests**

795 The authors declare no competing interests.

796 **Funding**

797 This work was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant:
798 KAW 2020.0239) and the Swedish Research Council (#2022-01562).

799 **Authors' contributions**

800 W.Z. conceived and designed the study. G.B. supplied clinical material. M.U., G.B., W.Z. and F.E.,
801 collected and contributed data to the study. W.Z., J.W., A.Z., and X.W. performed the data analysis.
802 W.Z., J.W., A.Z., and X.W. drafted the manuscript. All authors read and approved the final manuscript.

803 **Acknowledgements**

804 Original human sensitive data was processed under Project sens2018115. The integrative multi-omics
805 analysis of the processed data was performed using computational resources provided by SNIC through
806 the Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project
807 Berzelius-2024-200. Part of this research was conducted using the UK Biobank Resource under
808 Application 99914. We thank the Plasma Profiling Facility at SciLifeLab in Stockholm for conducting
809 the Olink analyses and Dr. Linn Fagerberg for data collection and data analysis in the S3WP program.
810 We also thank the Proteomics and Metabolomics Platform at Guangzhou Laboratory for conducting the
811 cell-line validation experiment using liquid chromatography-time-of-flight mass spectrometry (Q-TOF).
812 We also express our gratitude to Yanfen Hong for her assistance with data acquisition and analysis.

813 **Authors' information**

814 Science for Life Laboratory, Department of Biomedical and Clinical Sciences (BKV), Linköping
815 University, Linköping, Sweden.

816 Jing Wang, Alberto Zenere, Xingyue Wang and Wen Zhong

817

818 Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, and
819 Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

Göran Bergström

Department of Protein Science, KTH - Royal Institute of Technology, Stockholm, Sweden

Fredrik Edfors and Mathias Uhlén

References

1. Gieger, C. *et al.* Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum. *PLOS Genet.* **4**, e1000282 (2008).
2. Chen, L. *et al.* Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome. *Nat. Med.* **28**, 2333–2343 (2022).
3. Robinson, J. L. *et al.* An Atlas of Human Metabolism. *Sci. Signal.* **13**, eaaz1482 (2020).
4. Chen, Y. *et al.* Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. *Nat. Genet.* **55**, 44–53 (2023).
5. Hornburg, D. *et al.* Dynamic lipidome alterations associated with human health, disease and ageing. *Nat. Metab.* **5**, 1578–1594 (2023).
6. Merino, J., Udler, M. S., Leong, A. & Meigs, J. B. A Decade of Genetic and Metabolomic Contributions to Type 2 Diabetes Risk Prediction. *Curr. Diab. Rep.* **17**, 135 (2017).
7. Shin, S.-Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat. Genet.* **46**, 543–550 (2014).
8. Long, T. *et al.* Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. *Nat. Genet.* **49**, 568–578 (2017).
9. Surendran, P. *et al.* Rare and common genetic determinants of metabolic individuality and their effects on human health. *Nat. Med.* **28**, 2321–2332 (2022).
10. Lotta, L. A. *et al.* A cross-platform approach identifies genetic regulators of human metabolism and health. *Nat. Genet.* **53**, 54–64 (2021).
11. Illig, T. *et al.* A genome-wide perspective of genetic variation in human metabolism. *Nat. Genet.* **42**, 137–141 (2010).

12. Bomba, L. *et al.* Whole-exome sequencing identifies rare genetic variants associated with human plasma metabolites. *Am. J. Hum. Genet.* **109**, 1038–1054 (2022).

13. Karjalainen, M. K. *et al.* Genome-wide characterization of circulating metabolic biomarkers. *Nature* 1–9 (2024) doi:10.1038/s41586-024-07148-y.

14. Cirulli, E. T. *et al.* Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk. *Cell Metab.* **29**, 488-500.e2 (2019).

15. Watanabe, K. *et al.* Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention. *Nat. Med.* **29**, 996–1008 (2023).

16. Ottosson, F. *et al.* Metabolome-Defined Obesity and the Risk of Future Type 2 Diabetes and Mortality. *Diabetes Care* **45**, 1260–1267 (2022).

17. Xu, T. *et al.* Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. *BMC Med.* **11**, 60 (2013).

18. Bar, N. *et al.* A reference map of potential determinants for the human serum metabolome. *Nature* **588**, 135–140 (2020).

19. Asnicar, F. *et al.* Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. *Nat. Med.* **27**, 321–332 (2021).

20. Altmaier, E. *et al.* Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism. *Eur. J. Epidemiol.* **29**, 325–336 (2014).

21. Chen, L. *et al.* Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome. *Nat. Med.* **28**, 2333–2343 (2022).

22. Stamp, T. C. B. & Round, J. M. Seasonal Changes in Human Plasma Levels of 25-Hydroxyvitamin D. *Nature* **247**, 563–565 (1974).

23. Brewerton, T. D., Putnam, K. T., Lewine, R. R. J. & Risch, S. C. Seasonality of cerebrospinal fluid monoamine metabolite concentrations and their associations with meteorological variables in humans. *J. Psychiatr. Res.* **99**, 76–82 (2018).

24. Martynova, E. *et al.* Seasonal Changes in Serum Metabolites in Multiple Sclerosis Relapse. *Int. J. Mol. Sci.* **24**, 3542 (2023).

873 25. Ma, Y. *et al.* Seasonal variation in food intake, physical activity, and body weight in a
874 predominantly overweight population. *Eur. J. Clin. Nutr.* **60**, 519–528 (2006).
875 26. Küçükerdönmez, Ö. & Rakicioğlu, N. The effect of seasonal variations on food consumption,
876 dietary habits, anthropometric measurements and serum vitamin levels of university students. *Prog.*
877 *Nutr.* **20**, (2018).
878 27. Chaleckis, R., Murakami, I., Takada, J., Kondoh, H. & Yanagida, M. Individual variability in
879 human blood metabolites identifies age-related differences. *Proc. Natl. Acad. Sci.* **113**, 4252–4259
880 (2016).
881 28. Chen, Z.-Z. *et al.* Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment
882 Effect in the Diabetes Prevention Program. *Diabetes* **68**, 2337–2349 (2019).
883 29. Tebani, A. *et al.* Integration of molecular profiles in a longitudinal wellness profiling cohort.
884 *Nat. Commun.* **11**, 4487 (2020).
885 30. Kim, K. *et al.* Mealtime, temporal, and daily variability of the human urinary and plasma
886 metabolomes in a tightly controlled environment. *PloS One* **9**, e86223 (2014).
887 31. Ala-Korpela, M. *et al.* Cross-sectionally Calculated Metabolic Aging Does Not Relate to
888 Longitudinal Metabolic Changes-Support for Stratified Aging Models. *J. Clin. Endocrinol. Metab.*
889 **108**, 2099–2104 (2023).
890 32. Bergström, G. *et al.* The Swedish CArdioPulmonary BioImage Study: objectives and design. *J.*
891 *Intern. Med.* **278**, 645–659 (2015).
892 33. Zhong, W. *et al.* Next generation plasma proteome profiling to monitor health and disease. *Nat.*
893 *Commun.* **12**, 2493 (2021).
894 34. Zhong, W. *et al.* Whole-genome sequence association analysis of blood proteins in a
895 longitudinal wellness cohort. *Genome Med.* **12**, 53 (2020).
896 35. Danecek, P. & McCarthy, S. A. BCFtools/csq: haplotype-aware variant consequences.
897 *Bioinformatics* **33**, 2037–2039 (2017).
898 36. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
899 datasets. *GigaScience* **4**, 7 (2015).

37. McLaren, W. *et al.* Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. *Bioinformatics* **26**, 2069–2070 (2010).

38. Diab, J. *et al.* Lipidomics in Ulcerative Colitis Reveal Alteration in Mucosal Lipid Composition Associated With the Disease State. *Inflamm. Bowel Dis.* **25**, 1780–1787 (2019).

39. Wishart, D. S. *et al.* HMDB 5.0: the Human Metabolome Database for 2022. *Nucleic Acids Res.* **50**, D622–D631 (2022).

40. Arya, S., Mount, D., Kemp, S. E. & Jefferis, G. RANN: Fast Nearest Neighbour Search (Wraps ANN Library) Using L2 Metric. (2019).

41. Hahsler, M., Piekenbrock, M. & Doran, D. dbscan: Fast Density-Based Clustering with R. *J. Stat. Softw.* **91**, 1–30 (2019).

42. Csárdi, G. *et al.* igraph: Network Analysis and Visualization. (2024).

43. Hinrichs, A. S. *et al.* The UCSC Genome Browser Database: update 2006. *Nucleic Acids Res.* **34**, D590–D598 (2006).

44. Mägi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. *BMC Bioinformatics* **11**, 288 (2010).

45. Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest Package: Tests in Linear Mixed Effects Models. *J. Stat. Softw.* **82**, 1–26 (2017).

46. Halekoh, U. & Højsgaard, S. A Kenward-Roger Approximation and Parametric Bootstrap Methods for Tests in Linear Mixed Models – The R Package pbkrtest. *J. Stat. Softw.* **59**, 1–32 (2014).

47. Kleiber, C. & Zeileis, A. AER: Applied Econometrics with R. Springer-Verlag (2008).

48. R Core Team and contributors worldwide. The R Stats Package.

49. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK Biobank. *Nature* **622**, 329–338 (2023).

50. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).

51. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. in *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining* 785–794 (Association for Computing Machinery, New York, NY, USA, 2016). doi:10.1145/2939672.2939785.

52. Laboratory, N.-R. A. verification: Weather Forecast Verification Utilities. (2015).

53. McInnes, L., Healy, J., Saul, N. & Großberger, L. UMAP: Uniform Manifold Approximation and Projection. *J. Open Source Softw.* **3**, 861 (2018).

54. Oksanen, J. *et al.* vegan: Community Ecology Package. (2022).

55. Allaire, J. J. *et al.* networkD3: D3 JavaScript Network Graphs from R. (2017).

56. Kolde, R. pheatmap: Pretty Heatmaps. (2019).

57. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular visualization in R. *Bioinforma. Oxf. Engl.* **30**, 2811–2812 (2014).

58. Read, Q. D. & Brunson, J. C. ggalluvial: Alluvial Plots in 'ggplot2'. (2023).

59. Wickham, H. ggplot2. *WIREs Comput. Stat.* **3**, 180–185 (2011).

60. Team, R. R: A language and environment for statistical computing. *MSOR Connect.* (2014).

61. Wu, G. Amino acids: metabolism, functions, and nutrition. *Amino Acids* **37**, 1–17 (2009).

62. DeBerardinis, R. J. *et al.* Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc. Natl. Acad. Sci.* **104**, 19345–19350 (2007).

63. Rodriguez-Cuenca, S., Pellegrinelli, V., Campbell, M., Oresic, M. & Vidal-Puig, A. Sphingolipids and glycerophospholipids - The 'ying and yang' of lipotoxicity in metabolic diseases. *Prog. Lipid Res.* **66**, 14–29 (2017).

64. Grabner, G. F., Xie, H., Schweiger, M. & Zechner, R. Lipolysis: cellular mechanisms for lipid mobilization from fat stores. *Nat. Metab.* **3**, 1445–1465 (2021).

65. McMahon, H. T. & Gallop, J. L. Membrane curvature and mechanisms of dynamic cell membrane remodelling. *Nature* **438**, 590–596 (2005).

66. Chang, E. & Kim, Y. Vitamin D decreases adipocyte lipid storage and increases NAD-SIRT1 pathway in 3T3-L1 adipocytes. *Nutr. Burbank Los Angel. Cty. Calif* **32**, 702–708 (2016).

67. Pedersen, E. B. *et al.* Plasma amino acids in Greenlanders and Danes: influence of seasons, residence, ethnicity, and diet. *Am. J. Hum. Biol. Off. J. Hum. Biol. Counc.* **18**, 99–111 (2006).

68. Catoire, M. *et al.* Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise. *Proc. Natl. Acad. Sci. U. S. A.* **111**, E1043-1052 (2014).

956 69. A, G. *et al.* Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome
957 proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress.
958 *Circ. Res.* **106**, (2010).
959 70. Wu, Q. *et al.* Gamma-glutamyl-leucine levels are causally associated with elevated cardio-
960 metabolic risks. *Front. Nutr.* **9**, 936220 (2022).
961 71. Badoud, F. *et al.* Serum and adipose tissue amino acid homeostasis in the metabolically healthy
962 obese. *J. Proteome Res.* **13**, 3455–3466 (2014).
963 72. Teo, C. H., Wong, A. C. H., Sivakumaran, R. N., Parhar, I. & Soga, T. Gender Differences in
964 Cortisol and Cortisol Receptors in Depression: A Narrative Review. *Int. J. Mol. Sci.* **24**, 7129 (2023).
965 73. Aranda, J. V. *et al.* Metabolism of Theophylline to Caffeine in Human Fetal Liver. *Science* **206**,
966 1319–1321 (1979).
967 74. Diamanti, K. *et al.* Integration of whole-body [18F]FDG PET/MRI with non-targeted
968 metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes. *Sci.*
969 *Rep.* **10**, 8343 (2020).
970 75. Oudemans-van Straaten, H. M., Bosman, R. J., Treskes, M., van der Spoel, H. J. & Zandstra,
971 D. F. Plasma glutamine depletion and patient outcome in acute ICU admissions. *Intensive Care Med.*
972 **27**, 84–90 (2001).
973 76. Lacey, J. M. & Wilmore, D. W. Is Glutamine a Conditionally Essential Amino Acid? *Nutr. Rev.*
974 **48**, 297–309 (1990).
975 77. Wen, Z. *et al.* Time-resolved online analysis of the gas- and particulate-phase of cigarette smoke
976 generated by a heated tobacco product using vacuum ultraviolet photoionization mass spectrometry.
977 *Talanta* **238**, 123062 (2022).
978 78. Benson, M. D. *et al.* Protein-metabolite association studies identify novel proteomic
979 determinants of metabolite levels in human plasma. *Cell Metab.* **35**, 1646-1660.e3 (2023).
980 79. Van Dijk, G. The Role of Leptin in the Regulation of Energy Balance and Adiposity. *J.*
981 *Neuroendocrinol.* **13**, 913–921 (2001).

982 80. de Castro, M. A., Baltar, V. T., Marchioni, D. M. L. & Fisberg, R. M. Sex differences in serum
983 leptin and its relation to markers of cardiometabolic risk in middle-aged adults: Evidence from a
984 population-based study. *Nutrition* **31**, 491–497 (2015).
985 81. Fluhr, L. *et al.* Gut microbiota modulates weight gain in mice after discontinued smoke
986 exposure. *Nature* **600**, 713–719 (2021).
987 82. Lewis, C. M. *et al.* Genome scan meta-analysis of schizophrenia and bipolar disorder, Part II:
988 schizophrenia. *Am. J. Hum. Genet.* **73**, 34–48 (2003).
989 83. Litwack, E. D., Babey, R., Buser, R., Gesemann, M. & O'Leary, D. D. M. Identification and
990 characterization of two novel brain-derived immunoglobulin superfamily members with a unique
991 structural organization. *Mol. Cell. Neurosci.* **25**, 263–274 (2004).
992 84. Takeuchi, A. & O'Leary, D. D. M. Radial Migration of Superficial Layer Cortical Neurons
993 Controlled by Novel Ig Cell Adhesion Molecule MDGA1. *J. Neurosci.* **26**, 4460–4464 (2006).
994 85. Dócs, K. *et al.* The Ratio of 2-AG to Its Isomer 1-AG as an Intrinsic Fine Tuning Mechanism
995 of CB1 Receptor Activation. *Front. Cell. Neurosci.* **11**, (2017).
996 86. Viveros, M. P., Marco, E. M. & File, S. E. Endocannabinoid system and stress and anxiety
997 responses. *Pharmacol. Biochem. Behav.* **81**, 331–342 (2005).
998 87. Kersten, S. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma
999 lipid metabolism. *J. Lipid Res.* **62**, 100150 (2021).
1000 88. Kumar, A. A. *et al.* Plasma leptin level mirrors metabolome alterations in young adults.
1001 *Metabolomics Off. J. Metabolomic Soc.* **16**, 87 (2020).
1002 89. Lawler, K. *et al.* Leptin-Mediated Changes in the Human Metabolome. *J. Clin. Endocrinol.*
1003 *Metab.* **105**, 2541–2552 (2020).
1004 90. Alberti, K. G. M., Zimmet, P. & Shaw, J. The metabolic syndrome—a new worldwide definition.
1005 *The Lancet* **366**, 1059–1062 (2005).
1006 91. Stelmach-Mardas, M. *et al.* Seasonality of food groups and total energy intake: a systematic
1007 review and meta-analysis. *Eur. J. Clin. Nutr.* **70**, 700–708 (2016).

1008 92. van Ooijen, A. M. J., van Marken Lichtenbelt, W. D., van Steenhoven, A. A. & Westerterp, K.
1009 R. Seasonal changes in metabolic and temperature responses to cold air in humans. *Physiol. Behav.*
1010 **82**, 545–553 (2004).
1011 93. Dopico, X. C. *et al.* Widespread seasonal gene expression reveals annual differences in human
1012 immunity and physiology. *Nat. Commun.* **6**, 7000 (2015).
1013 94. Wucher, V., Sodaei, R., Amador, R., Irimia, M. & Guigó, R. Day-night and seasonal variation
1014 of human gene expression across tissues. *PLoS Biol.* **21**, e3001986 (2023).
1015 95. Suhre, K. *et al.* Human metabolic individuality in biomedical and pharmaceutical research.
1016 *Nature* **477**, 54–60 (2011).
1017

Figures

Fig. 1



Fig. 1 Longitudinal multi-omics profiling and co-expression analysis of human plasma metabolites in 101 healthy individuals.

a Overview of the study design for the S3WP project, detailing the longitudinal data collection strategy over six visits in two years (created with biorender.com). This included whole-genome sequencing,

proteomics, metabolomics, lipidomics, clinical measurements, and lifestyle questionnaires from 101 individuals. A total of 527 identified metabolites were categorized into 9 major classes. **b** UMAP clustering of the 527 metabolites showing their co-expression patterns, color-coded by their classes and grouped by co-expression clusters. **c** Sankey plot showing the distribution of metabolic classes across the clusters. **d** Bar plot showing the functional enrichment results of the metabolite clusters using Fisher's exact test.

Fig. 2



Fig. 2 Inter- and intra-individual variability of plasma metabolites and seasonal influences

a The inter-individual and intra-individual variations of plasma metabolite levels, calculated as the coefficient of variation (CV) for each metabolite within each visit and across all participants, color-coded by metabolite classes. **b** Seasonal variation analysis of plasma metabolites using amplitude analysis, color-coded by metabolic classes. Y-axis showing the adjusted *p*-values with multiple test corrections using Benjamini and Hochberg method**.** **c** Heatmap showing the scaled levels of 121 metabolites with significant seasonal variations across 12 months. **d-g** Plasma metabolite levels throughout the year for metabolites in Cluster M1-M4. **h** Pathway enrichment analysis of metabolites within each seasonal cluster. Significantly enriched pathways were defined with adjusted *P*-values < 0.05 (Fisher's exact test with multiple test corrections using using Benjamini and Hochberg method). **i**, Vitamin D concentration levels across 12 months during the study period. **j**, Succinylcarnitine levels over 12 months as an example of metabolites in Cluster M3. Each line represents an individual; red lines indicate females and blue lines indicate males. Regression lines are added using trigonometric functions.

Fig. 3



Fig. 3 Influence of clinical measurements and lifestyle factors on metabolite levels.

1051 **a** Canonical correspondence analysis (CCA) showing correlations between plasma metabolite levels,
1052 clinical measurements and lifestyle variables. The upper and left bar plots show the estimated linear
1053 regression coefficients for clinical and lifestyle variables with respect to CCA1 and CCA2. **b, d** Volcano
1054 plots showing the impacts of sex (**b**) and BMI (**d**) on plasma metabolite levels (Kenward-Roger
1055 approximation with Benjamini and Hochberg correction). **c** Concentration of gamma-glutamylleucine
1056 across four study visits, shown as an example of a sex-associated metabolite. Each line represents an
1057 individual; red lines indicate females and blue lines indicate males. **e** Scatter plot showing the
1058 correlation between glutamic acid concentration and BMI, color-coded by BMI.

1059 **Fig. 4**



1060

1061 **Fig. 4 Genome-wide association analysis of the genetic regulation of the plasma metabolites.**

1062 **a** Manhattan plot showing the identified mQTLs in the study. Significant loci are annotated based on
1063 the closest gene, with colors indicating the class of the corresponding metabolite. **b** Chord diagram of
1064 loci shared ($r^2 > 0.2$) among metabolites in GWAS study. Line thickness is proportionate to the -
1065 Log10(*P*). **c** Manhattan plot of butyrylcarnitine showing the genome locations of all associated mQTLs.

d Boxplot showing the association between plasma levels of butyrylcarnitine and the genotype of rs34673751, color-coded by the genotype of rs34673751. **e** Plasma levels of butyrylcarnitine across study visits; each individual is represented by a line; color-coded by the genotype of rs34673751. **f-g** Western blot showing increased butyrylcarnitine levels in the ACADS know-down 293T cell lines compared to the control group. **h** Manhattan plot for 4-androsten-3alpha,17alpha-diol monosulfate (2), showing the associated genetic loci. **i** Boxplot showing the association between plasma levels of 4-androsten-3alpha,17alpha-diol monosulfate (2) and the genotype of rs45446698. **j** Plasma levels of butyrylcarnitine across study visits; each individual is represented by a line; color-coded by the genotype of rs34673751.

Fig. 5



Fig. 5 Influence of genetic, clinical and lifestyle factors on plasma metabolite level variability.

a Overview of influence of genetic, clinical and lifestyle factors on the plasma metabolite level variability. b Barplot showing the variance explanation fraction for each component across all 22

genetic-related metabolites, color-coded by the variable classes. c Barplot showing the top 25 metabolites most strongly associated with clinical components. d Barplot showing the top 25 metabolites most strongly associated with lifestyle components.

Fig. 6



1085 **Fig. 6 Characterization of protein-metabolite network**

1086 **a** Network presenting the top 200 significant protein-metabolite pairs identified by the linear mixed
1087 model (LMM) (FDR-adjusted $P < 0.05$). Solid circles represent proteins in the inner ring, color-coded
1088 by protein annotation. Squares represent metabolites in the outer ring, color-coded by different
1089 metabolite-related influence factors. Pairs of related proteins and metabolites are connected by dashed
1090 lines (indicating correlations supported by LMM results) and solid lines (indicating correlations
1091 supported by both the LMM and Mendelian randomization (MR) analysis). Green lines indicate positive
1092 correlations between proteins and metabolites in the LMM, while red lines indicate negative
1093 correlations. **b** Scatter plot showing the correlation between aceturic acid concentration and LEP, color-
1094 coded by sex. **c** Scatter plot showing the correlation between 1-Arachidonoylglycerol (1-AG)
1095 concentration and MDGA1, color-coded by different genotypes of rs9349050. **d** Manhattan plot for
1096 MDGA1 protein, showing the associated genetic variants with plasma levels of MDGA1. One of the
1097 most significant SNP (rs9349050) was used as an instrumental variable in the MR analysis. **e** UMAP
1098 clustering of the protein-metabolite profiles of the analyzed samples, color-coded by individual with
1099 lines connecting the visits for each individual. **f, g** Bar plots showing the variance explanation fraction
1100 of different genetic, clinical and lifestyle factors, calculated from linear mixed modeling, for UMAP1
1101 (**f**) and UMAP2 (**g**). **h, i** Distribution of betweenness score of proteins (**h**) and metabolites (**i**) in three
1102 tiers. **j, k** Dot plots highlighting the Tier 1 proteins (**j**) and metabolites (**k**)

Fig. 7



Fig. 7 Predictive models for metabolic risk assessment

a Measurements of classical metabolic risk indicators, including HDL, BMI, SBP, TG and Gluc, compared between high risk and low risk groups. **b** Measurements of ALAT, GGT, urate, TNT and WBC for the high risk and low risk groups. **c** Area under the curve (AUC) of prediction models based

on six different combinations of plasma proteins and metabolites: i) all proteins and metabolites; ii) tier 1 proteins and metabolites; iii) all proteins; iv) tier 1 proteins; v) all metabolites; vi) tier 1 metabolites. The AUC values were calculated by performing random sampling 100 times to account for variability. **d** Average receiver operating characteristic (ROC) curves for the predictive models for the six combination of plasma proteins and metabolites for predicting metabolic risk levels. **e, f** Linear model coefficients obtained using Tier 1 proteins (**e**) and metabolites (**f**) as independent variables and a dummy variable to indicate if the sample belonged to the high risk or ow risk group. **g** Tier 1 proteins' profiles of healthy individuals, compared with obesity, T2D, gout or hyperthyroidism in the UK Biobank. **h** Average ROC curves obtained using Tier 1 proteins to predict individuals with either obesity, type 2 diabetes (T2D), gout, hyperthyroidism in the UK Biobank database. **i** Alluvial plot showing the risk level of individual samples across visits. The y-axis represents the individuals involved in the study, with colors indicating different risk levels. **j** BMI levels of the individual W0010 during the study visits. **k** Changes in Tier 1 proteins over time in individual W0010 who lost a significant amount of weight (15.4kg) between visit 3 and visit 4. **l** Average ROC curve of predictive models using Tier 1 proteins to predict future obesity in the UK Biobank. The 95% confidence intervals (CI) of ROC curves were plotted in **d, h, k** Red; High risk group, blue; Low risk group. High density lipoprotein, HDL; body mass index, BMI; systolic blood pressure, SBP; triglycerides, TG; fasting glucose, Gluc; alanine aminotransferase, ALAT; gamma glutamyltransferase, GGT, troponin T, TNT; white blood cells count, WBC.

Additional file 1

Supplementary Methods and Figures. Additional methods on experimental validation and figures S1-S6.

Fig. S1 Co-expression clustering of 527 analyzed metabolites.

Fig. S2 Seasonal variation analysis of plasma metabolites and proteins.

Fig. S3 Mendelian randomization protein-metabolite network.

Fig. S4 Associations between Tier 1 proteins and metabolic diseases.

1136 **Fig. S5** Association between Tier 1 proteins and obesity.

1137 **Fig. S6** Prediction of future obesity in the UK Biobank.

1138 Additional file 2

1139 Table S1-S15.

1140 **Table S1.** Complete list of analyzed metabolites, proteins, and clinical parameters.

1141 **Table S2.** Classification and co-expression patterns of 527 analyzed metabolites.

1142 **Table S3.** Functional enrichment analysis of metabolite co-expression clusters.

1143 **Table S4.** Inter- and intra-individual variations of 527 analyzed metabolites.

1144 **Table S5.** Plasma metabolites with significant seasonal variation.

1145 **Table S6.** Temporal co-expression patterns of seasonal associated metabolites

1146 **Table S7.** Pathway enrichment analysis of metabolite co-expression clusters.

1147 **Table S8.** Temporal co-expression patterns of seasonally associated proteins.

1148 **Table S9.** Sex-associated plasma metabolites.

1149 **Table S10.** BMI-associated plasma metabolites.

1150 **Table S11.** Summary of identified independent mQTLs

1151 **Table S12.** Meta-analysis of identified independent mQTLs.

1152 **Table S13.** Contributions of genetics, lifestyle, and clinical factors to the variability of plasma
1153 metabolites.

1154 **Table S14.** Comprehensive mixed-effect modeling analysis of protein-metabolite associations.

1155 **Table S15.** Summary of one-sample mendelian randomization analysis.